Articles tagged with Sars Cov 2
Researchers discover piperlongumine (PL), extracted from long pepper, as a potent antiviral treatment for SARS-CoV-2. PL delays disease progression and reduces lung inflammation in mice infected with alpha, delta, and omicron variants, offering a potential solution to combat upcoming outbreaks.
Researchers from UCalgary and the World Health Organization found that people with hybrid immunity have the highest level of protection against severe illness and reinfection, offering a key finding for public policy makers. The study suggests vaccination should be prioritized even among those who have had COVID-19.
Researchers found SARS-CoV-2 virus in almost all plane wastewater at three UK airports during a period of COVID restrictions. The study suggests that wastewater testing could be used to monitor the general health of passengers on flights entering the country, potentially capturing 8-14% of SARS-CoV-2 cases.
A study of 1,832 US adults found that unvaccinated individuals and those with moderate to severe acute illness symptoms were more likely to experience prolonged symptoms. Vaccination significantly reduced the risk of pulmonary, diabetes, neurological, and mental health encounters six months after COVID-19 onset.
Researchers at Linköping University discovered that COVID-19 patients experience negative impacts on their immune cells six months after infection. The study highlights a connection between disease severity and immune cell dysfunction, suggesting the need for early antiviral treatment to prevent prolonged inflammation.
Long COVID is a systemic condition with over 100 reported symptoms, including fatigue, anxiety, and breathing issues. Treatment focuses on symptom management through structured programs and guideline-directed mental health supports.
A new study by Osaka University researchers demonstrates that the endothelial cell-specific protein Robo4 plays a crucial role in reducing mortality in severe infection. By upregulating Robo4 expression, a drug treatment can decrease vascular permeability and increase survival rates.
Scientists have identified a new class of 'bivalent' antibodies that can bind to two viral targets at once, neutralizing multiple Omicron variants. These potent antibodies retain efficacy against early SARS-CoV-2 variants and several later Omicron sub-lineages.
Researchers found that high levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months, with a 90% lower risk of re-infection. Participants with prior infections generated stronger mucosal immune responses to Omicron breakthrough infections.
A study of 4,768 patients with cancer found that SARS-CoV-2 infection led to delayed or discontinued cancer treatment, exacerbating existing survival inequities. Racial and area-level social determinants were associated with these delays.
Researchers found a genetic alteration in the SARS-CoV-2 spike protein that redirects the virus into a storage compartment within cells, reducing its surface exposure. This change may affect the immune system's ability to identify and kill infected cells.
A new study found that COVID-19 primarily affected patients with a moderate to critical course, often with comorbidities, whereas many had mild courses despite metastatic melanoma and systemic therapy, recommending continued treatment whenever possible.
Researchers explore challenges and propose next-generation vaccine strategies for mucosa-replicating viruses, which evade full immune response due to short incubation periods and nasal mucosa replication. To overcome immune tolerance, significant knowledge gaps must be filled on ideal vaccine formulations, dosage, and techniques.
A mathematical model predicts the long-term effectiveness of COVID-19 vaccine booster doses in various patient populations, including those with healthy immune systems and cancer patients. The model suggests that robust antibody-based responses can be achieved through booster doses, but may wane quickly in immunosuppressed individuals.
Researchers developed a CSIC vaccine that fully protects against SARS-CoV-2 infection in the brain and prevents associated brain damage. The MVA-CoV2-S vaccine candidate demonstrates sterilizing immunity and was effective even after reinfection with the virus.
A new study in Portugal's population shows that hybrid immunity from vaccination and previous SARS-CoV-2 infections confers up to 8 months of protection against omicron BA.5. The study found that protection remains high after 8 months, with a stable level of around 65%.
A study by Brown University and Silent Spring Institute found that inexpensive DIY air filters called Corsi-Rosenthal boxes can significantly decrease indoor air concentrations of PFAS and phthalates. The boxes, made from MERV-13 filters, duct tape, a fan, and cardboard, reduced PFAS levels by 40% to 60% and phthalates by 30% to 60%.
A study in Serrana, Brazil showed that mass vaccination reduced severe cases and death rates even while gamma and delta variants were circulating. Vaccination coverage reached 80% of the target population.
A new rapid test developed by the University of Würzburg uses magnetic nanoparticles to detect antibodies against SARS-CoV-2 with high sensitivity. The test takes only a few seconds to produce reliable results, enabling faster diagnosis and treatment of infectious diseases.
A study found that acidification of aerosols post-exhalation significantly impacts viral load. Influenza A viruses are inactivated within minutes, while SARS-CoV-2 requires days at typical indoor pH levels.
A recent study on Omicron's origins has been retracted due to contaminated genome sequences, casting doubt on the variant's emergence timeline. The Charité team, led by Prof. Jan Felix Drexler, is conducting a review of their analyses to address these concerns.
Researchers developed a method to estimate seroprevalence using blood donation samples, offering insights into the first year of the COVID-19 epidemic in Brazil. The study found significant differences among regions and subgroups, highlighting the need for real-time tracking and forecasting of future waves.
A new respiratory vaccine has been shown to provide complete protection against lethal SARS-CoV-2 challenge in mice. The vaccine uses a DNA encoding a viral protein and is delivered through the mucous membranes, targeting immune cells in the nose and lungs.
A new model created by Weill Cornell Medicine investigators found that pregnant individuals had a 50% lower exposure to SARS-CoV-2 compared to the general population in the earliest months of the pandemic. This protection was likely due to shielding measures, including masking and social distancing.
Researchers developed a machine learning model that uses microbiome data from wastewater to estimate the number of individuals represented in a sample. The method was trained on over 1,100 people's samples and can be used to link wastewater properties to individual-level data.
Researchers developed a method to produce SARS-CoV-2 RBD antigen using bio-engineered plants, offering a scalable solution for diagnostic assays and subunit vaccines. This breakthrough could facilitate large-scale production of antigens, supporting global vaccination efforts.
Researchers have identified a compound that shows early promise at halting infections from a range of coronaviruses, including all variants of SARS-CoV-2 and the common cold. The findings reveal a potential path toward antiviral treatments that could be used against many different pathogens.
A recent study published in the American Journal of Obstetrics & Gynecology MFM found that pregnant individuals have a similar long-term immune response to SARS-CoV-2 mRNA vaccination as non-pregnant individuals. The study also showed that vaccination during pregnancy provides protection to unborn babies, which is essential for their C...
Researchers found that adult hospitalisations from Omicron-related SARS-CoV-2 infections were less severe than those from Delta infections. The Pfizer-BioNTech vaccine was effective in preventing hospitalisations and severe outcomes, even with increasing Omicron variant transmissibility.
A study of 390 participants found that involvement in patient-facing dental activities did not increase the risk of COVID-19 infection when controlled measures were in place. The study suggests that intensive control measures can mitigate the risk of SARS-CoV-2 transmission in dental clinical settings.
Researchers developed an accurate predictive model to distinguish between COVID-19 positive and negative test outcomes. The study found that symptom features, such as fever and difficulty breathing, play a significant role in predicting test results, with molecular tests yielding lower positive rates due to their dependence on viral load.
A team of researchers at Tokyo Medical and Dental University has designed and synthesized novel compounds that have the potential to be effective drugs against COVID-19. The compounds target the main protease enzyme of the SARS-CoV-2 virus, which is essential for viral replication.
The study analyzed 23,000 symptomatic individuals in King County, Washington, from June 2020 to July 2022. It found shifts in reported symptoms between SARS-CoV-2 variants and persistent racial and sociodemographic disparities in rhinovirus infection.
A new study suggests that the SARS-CoV-2 spike protein contributes to vascular leak, a dangerous release of fluids from blood vessels leading to respiratory failure. Researchers believe blocking this pathway could help prevent severe COVID-19 symptoms and shed light on other emerging infectious diseases.
Researchers at Karolinska Institutet discovered that SARS-CoV-2 infection triggers blood vessel formation in fat tissues, leading to thermogenic metabolism and significant weight loss. Blocking this process with an antiangiogenic drug restored weight loss in mice and hamsters infected with the virus.
Researchers identified two molecularly distinct subsets of long COVID symptoms with opposing gene expression patterns during acute COVID-19. These findings suggest multiple independent processes leading to different long COVID symptoms, which are already present during the acute infection.
The City of Tempe and Arizona State University have developed a unique partnership to track COVID-19 using wastewater-based epidemiology, providing early warning data for municipalities. The system has been shown to reliably predict SARS-CoV-2 levels in city ZIP codes up to 11 days ahead of clinical testing results.
A recent study identified several characteristics associated with a higher likelihood of post COVID-19 condition diagnosis. These include female sex, previous mental health disorders, and asthma. The study also found that use of outpatient care was substantially elevated among individuals with post COVID-19 condition.
Administration of vaccine boosters to nursing home residents significantly reduces SARS-CoV-2 infections and hospitalizations. The study suggests that booster vaccination may play a crucial role in preventing COVID-19-related morbidity and mortality among vulnerable populations.
A recent study published in Frontiers in Medicine found that COVID-19 vaccines significantly reduce the likelihood of reinfection and severe symptoms. Vaccinated individuals who have recovered from the virus have a 50% to 60% lower risk of reinfection compared to those who are not vaccinated.
Scientists at Dana-Farber Cancer Institute have developed a potent drug that neutralizes SARS-CoV-2 and its variants by mimicking the ACE2 receptor, making it effective against emerging antibody-resistant strains. The investigational drug, DF-COV-01, could also be used to treat future coronaviruses.
New research reveals that bat virus relatives of MERS-CoV efficiently bind to bat ACE2 receptors as an entry point into cells. However, these viruses only weakly bind to human ACE2 cell receptors and are not known to cause disease outbreaks in people.
A study suggests that visceral fat cells, rather than subcutaneous fat cells, are more susceptible to infection by the COVID-19 virus. This increased susceptibility leads to a higher viral load and production of pro-inflammatory cytokines, which can exacerbate severe disease.
A University of Ottawa-led team identified a new entry route for SARS-CoV-2 using metalloproteinases, which may lead to more widespread cell infection and severe illness. The study suggests that variants like the Delta strain may prefer this entry method, while others like Omicron do not.
Researchers developed novel liquid-coated air filters that capture viable bacterial and viral samples for analysis. The filters show promise in improving early pathogen detection and aerosol sampling efforts.
The study found that COVID-19 restrictions led to decreased balance ability, higher body fat levels, and worsened lifestyle habits in Japanese children. The researchers suggest that quality of exercise, rather than quantity, was the main factor contributing to these changes.
A large study found that most Canadian children and adults younger than 60 had been exposed to SARS-CoV-2 through a combination of vaccination and infection. The study, conducted in British Columbia, shows a dramatic change in the proportion of the population with antibodies over the first 2.5 years of the pandemic.
Researchers identify an off-patent liver disease drug that can prevent SARS-CoV-2 entry into cells, potentially offering protection against future variants. The study used a unique combination of 'mini-organs', animal studies, and human subjects to demonstrate the drug's effectiveness.
Researchers used computer simulations to show that SARS-CoV-2 variants can attach to host cells in both bats and humans using their spike proteins. The study's findings suggest a significant risk of mammalian cross-species infectivity, contradicting initial expectations of reduced transmission.
Researchers at Aarhus University found a link between lipid kinase VPS34 and viral protection in the kidneys. The study used multiomics analysis to show that blocking lipid kinase could reduce viral entry and increase nutrient retention, offering potential new treatments for kidney diseases and infections.
Research suggests that long COVID patients share similar lingering negative effects on physical, mental, and social well-being with individuals who have other illnesses. The study found moderate-to-severe residual symptoms in 40% of COVID-positive participants and 54% of those who tested negative.
A follow-up study found that the 2-dose vaccines still provided protection against lung disease one year after vaccination as infants. The adjuvanted protein vaccine candidate maintained higher levels of neutralizing antibodies and provided superior protection compared to the mRNA vaccine.
Researchers found viruses with Omicron-specific mutations in COVID-19 patients in six African countries two months before the variant was detected. The study suggests that Omicron emerged gradually, evolving from existing human immunity, and spreading rapidly across Africa before global detection.
Researchers have found that experimental vaccines, including a protein-based vaccine candidate with an adjuvant, provide superior protection against lung disease and higher levels of neutralizing antibodies compared to mRNA vaccines. The results inform the optimization and development of COVID-19 vaccines for young infant populations.
A study published in PLOS Medicine suggests that primary vaccination provides moderate protection against Omicron infection regardless of prior infection history. However, the additional benefit of an original booster dose is unclear in people who have previously experienced COVID-19 infection.
A study of 1,000 adults found persistent poor physical and mental well-being at 3-month follow-up. Many reported moderate to severe impairments in well-being 3 months after symptomatic illness.
A new serological test, PepSeq, allows scientists to quickly test antibody binding against hundreds of thousands of protein targets, helping prepare for and respond to pandemics. The technology identifies specific antibodies that provide protection against infection, holding promise for developing effective vaccines and treatments.
A global Phase 2/3 clinical trial found that vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members. The study showed a significant reduction in symptomatic cases among vaccinated household contacts and indicated that vaccines can play an important role in controlling future outbreaks.
Researchers discovered a novel interaction between the SARS-CoV-2 Spike protein and human Estrogen Receptor Alpha, which may contribute to severe coagulopathy in COVID-19 patients. The study suggests that modulating ER signaling could mitigate rare vaccine side effects.
Researchers found that antibodies against one of the two main domains of the SARS-CoV-2 viral entry machinery elicit a broad antibody response against many variants. This suggests strategies for clinical development of variant-resistant vaccines.